Search Clinical Trials

9 Results

Enrolling By Invitation
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (External Link)
There is a crisis in the treatment of the imminently suicidal patient. Acute Suicidal Depression (ASD) is a life-threatening illness which requires rapid relief. A number of behavioral programs with …
Baylor Role: Collaborator
Recruiting
Baylor Infant and Toddler Biomarker of Nutrition Study (External Link)
Early life nutrition is recognized as key determinant of short- and long-term health. However, a lack of objective, reliable, and valid methods to determine what exactly children makes it difficult …
Baylor Role: Lead Sponsor
Recruiting
Maternal Carotenoids Across Pregnancy Study (External Link)
What a pregnant person eats is important for their own health and the health of their infant during pregnancy and after birth. Fruits and vegetables contain colorful substances called "carotenoids" …
Baylor Role: Lead Sponsor
Completed
Examining Validity and Sensitivity of Pressure-Mediated Reflection Spectroscopy (External Link)
A diet rich in fruits and vegetables (F&Vs) is associated with lower risk of nutrition-related chronic diseases and all-cause mortality. Despite these benefits, the US population under-consumes F&Vs, with particularly …
Baylor Role: Collaborator
Terminated
Ketamine in Veterans With Gulf War Illness (External Link)
Recruitment for this study starts after protocol approval by the BCM IRB, MEDVAMC R&D, and DoD HRPO. All study procedures are for research only. Potential subjects will be recruited (i) …
Baylor Role: Lead Sponsor
Completed
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) (External Link)
The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in …
Baylor Role: Collaborator
Terminated
Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder (External Link)
This study will test the safety and efficacy of a single intravenous (IV) dose of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, in treatment-resistant OCD.
Completed
Optimization of IV Ketamine for Treatment Resistant Depression (External Link)
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a …
Baylor Role: Lead Sponsor
Completed
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications (External Link)
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will …
Baylor Role: Lead Sponsor